New website streamlines how FDA updates information used to help health care providers choose an appropriate treatment for a patient's infection.
Using a simple swab from the infection site, DxWound uses a special transport buffer that preserves the wound microbiome during transit.
VT-1598, an oral fungal CYP51 inhibitor, has shown high potency against pathogens such as molds, yeasts, and multi-drug resistant fungal pathogens (eg, Candida auris).
Compared with itraconazole, amphotericin treatment correlated with significantly faster clinical resolution and fungal clearance and with significantly lower rates of relapse and immune reconstitution inflammatory syndrome.
Enterovirus was found to be the most common etiology (50.9%), followed by unknown (18.7%), bacterial meningitis (13.9%), herpes simplex virus (8.3%), non-infectious (3.4%), fungal (2.7%), arboviruses (1.1%), and other viruses (0.8%).
"This case reinforces the role of tissue culture when histology fails to demonstrate a diagnosis and emphasizes the need for efficient communication between the pediatrician, otolaryngologist, and pathologist for timely excision," the authors write.
The labeling for Lamisil (terbinafine hydrochloride) Tablets and Oral Granules has been updated to include a new warning regarding the risk of thrombotic microangiopathy.
Dr. Reddy's Laboratories has announced the launch of Nystatin and Triamcinolone Acetonide Cream, the generic equivalent of Taro Pharmaceutical's Nystatin and Triamcinolone Acetonide Cream, USP 100,000/g 0.1%.
The Food and Drug Administration (FDA) has approved new labeling for Naftin (naftifine HCl cream 2%; Merz Pharmaceuticals) adding additional information regarding use in the pediatric population.
The CDC announced an alert in June 2016 requesting all clinicians, laboratory workers, infection control practitioners, and public health authorities report C. auris cases.
Both the tablet and intravenous (IV) formulations of posaconazole appeared to be safe and effective for primary prophylaxis against invasive fungal infections in patients with hematologic malignancies, according to results of a retrospective cohort study presented at IDWeek 2016.
Viamet has announced that the Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) and Fast Track designation to VT-1161, a novel treatment for recurrant vulvovaginal candidiasis (RVVC).
The Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to VT-1598 (Viamet) for the treatment of coccidioidomycosis, or Valley Fever.
The Food and Drug Administration (FDA) has approved an update to the labeling for Noxafil (posaconazole; Merck) regarding an interaction with vincristine.
The Food & Drug Administration has granted Orphan Drug designation to PUR1900 (Pulmatrix) for the treatment of pulmonary fungal infections in patients with cystic fibrosis (CF).
The Infectious Diseases Society of America (IDSA) announced the release of updated guidelines on the diagnosi sand treatment of major forms of aspergillosis. The full guidelines are published in Clinical Infectious Diseases.
Using the Drug Interaction Probability Scale this interaction scored a 7 out of 10 indicating probable interaction.
Lupin announced that the Food and Drug Administration (FDA) has granted final approval for Voriconazole Tablets and Oral Suspension, the generic version of Pfizer's Vfend.
The Food and Drug Administration (FDA) has granted Orphan Drug designation to VT-1598 (Viamet) for the treatment of coccidioidomycosis or Valley Fever, a common lung infection in the southwestern US.
Clinicians should be aware of this possible adverse event and monitor patients receiving concomitant drugs that may prolong the QT interval.
The Food and Drug Administration (FDA) is advising caution when prescribing oral fluconazole (Diflucan) in pregnancy after evaluating data from a Danish study that indicated a possible increased risk of miscarriage when used to treat yeast infections.
Sagent announced a voluntary recall of 1 lot of Fluconazole Injection, USP, 200mg/100mL due to the discovery of an out of specification impurity result.
Fagron, Inc. is voluntarily recalling certain lots of SyrSpend SF and SyrSpend SF Grape suspending agents used in various oral liquid compounded products due to the presence of Candida galli, a type of yeast.